218 related articles for article (PubMed ID: 19095843)
1. Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats.
Elkiweri IA; Zhang YL; Christians U; Ng KY; Tissot van Patot MC; Henthorn TK
Anesth Analg; 2009 Jan; 108(1):149-59. PubMed ID: 19095843
[TBL] [Abstract][Full Text] [Related]
2. Variable modulation of opioid brain uptake by P-glycoprotein in mice.
Dagenais C; Graff CL; Pollack GM
Biochem Pharmacol; 2004 Jan; 67(2):269-76. PubMed ID: 14698039
[TBL] [Abstract][Full Text] [Related]
3. Coadministration of P-glycoprotein modulators on loperamide pharmacokinetics and brain distribution.
Montesinos RN; Moulari B; Gromand J; Beduneau A; Lamprecht A; Pellequer Y
Drug Metab Dispos; 2014 Apr; 42(4):700-6. PubMed ID: 24398461
[TBL] [Abstract][Full Text] [Related]
4. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein.
Wandel C; Kim R; Wood M; Wood A
Anesthesiology; 2002 Apr; 96(4):913-20. PubMed ID: 11964599
[TBL] [Abstract][Full Text] [Related]
5. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
[TBL] [Abstract][Full Text] [Related]
6. Effect of Subchronic Intravenous Morphine Infusion and Naloxone-Precipitated Morphine Withdrawal on P-gp and Bcrp at the Rat Blood-Brain Barrier.
Chaves C; Gómez-Zepeda D; Auvity S; Menet MC; Crété D; Labat L; Remião F; Cisternino S; Declèves X
J Pharm Sci; 2016 Jan; 105(1):350-8. PubMed ID: 26554626
[TBL] [Abstract][Full Text] [Related]
7. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein Restricts Ocular Penetration of Loperamide across the Blood-Ocular Barriers: a Comparative Study in Mdr1a Knock-out and Wild Type Sprague Dawley Rats.
Tatke A; Janga KY; Avula B; Wang X; Jablonski MM; Khan IA; Majumdar S
AAPS PharmSciTech; 2018 May; 19(4):1662-1671. PubMed ID: 29520587
[TBL] [Abstract][Full Text] [Related]
9. Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein.
Kurnik D; Sofowora GG; Donahue JP; Nair UB; Wilkinson GR; Wood AJ; Muszkat M
Anesthesiology; 2008 Dec; 109(6):1092-9. PubMed ID: 19034106
[TBL] [Abstract][Full Text] [Related]
10. P-Glycoprotein on Blood-Brain Barrier Plays a Vital Role in Fentanyl Brain Exposure and Respiratory Toxicity in Rats.
Yu C; Yuan M; Yang H; Zhuang X; Li H
Toxicol Sci; 2018 Jul; 164(1):353-362. PubMed ID: 29669042
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects.
Saiz-Rodríguez M; Ochoa D; Herrador C; Belmonte C; Román M; Alday E; Koller D; Zubiaur P; Mejía G; Hernández-Martínez M; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):321-329. PubMed ID: 30281924
[TBL] [Abstract][Full Text] [Related]
12. Central Nervous System Distribution of an Opioid Agonist Combination with Synergistic Activity.
Griffith JI; Kim M; Bruce DJ; Peterson CD; Kitto KF; Mohammad AS; Rathi S; Fairbanks CA; Wilcox GL; Elmquist WF
J Pharmacol Exp Ther; 2022 Jan; 380(1):34-46. PubMed ID: 34663676
[TBL] [Abstract][Full Text] [Related]
13. Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings.
Ziesenitz VC; König SK; Mahlke N; Jantos R; Skopp G; Weiss J; Haefeli WE; Mikus G
Basic Clin Pharmacol Toxicol; 2013 Jul; 113(1):43-8. PubMed ID: 23480028
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist--loperamide.
Nozaki-Taguchi N; Yaksh TL
Anesthesiology; 1999 Jan; 90(1):225-34. PubMed ID: 9915332
[TBL] [Abstract][Full Text] [Related]
15. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
Sugimoto H; Hirabayashi H; Amano N; Moriwaki T
Drug Metab Dispos; 2013 Apr; 41(4):683-8. PubMed ID: 23340958
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the peripheral and central effects of the opioid agonists loperamide and morphine in the formalin test in rats.
Shannon HE; Lutz EA
Neuropharmacology; 2002 Feb; 42(2):253-61. PubMed ID: 11804622
[TBL] [Abstract][Full Text] [Related]
18. N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier.
Kannan P; Brimacombe KR; Zoghbi SS; Liow JS; Morse C; Taku AK; Pike VW; Halldin C; Innis RB; Gottesman MM; Hall MD
Drug Metab Dispos; 2010 Jun; 38(6):917-22. PubMed ID: 20212014
[TBL] [Abstract][Full Text] [Related]
19. Active transport of fentanyl by the blood-brain barrier.
Henthorn TK; Liu Y; Mahapatro M; Ng KY
J Pharmacol Exp Ther; 1999 May; 289(2):1084-9. PubMed ID: 10215691
[TBL] [Abstract][Full Text] [Related]
20. Uptake and efflux of the peptidic delta-opioid receptor agonist.
Dagenais C; Ducharme J; Pollack GM
Neurosci Lett; 2001 Apr; 301(3):155-8. PubMed ID: 11257421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
